Xenetic Biosciences XBIO
NASDAQ XBIO
$1.72 -0.21 (-10.88%)
As of: Oct 23, 2026 · 3:59 PM EDT

Xenetic Biosciences (XBIO) Gross Margin (2011 - 2017)

Updated

Xenetic Biosciences (XBIO) recorded Gross Margin of -14.15% in Q3 2017.

Analysis

Xenetic Biosciences (XBIO) Gross Margin (2011 - 2017) Analysis & Trends

For FY2013, Xenetic Biosciences reported Gross Margin of 100.00%, up 15.27 percentage points from FY2012.

  • Across earlier years, Gross Margin came in at 84.73% in FY2012.
  • The Q3 2017 figure is the highest quarterly Gross Margin since Q3 2013.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Eli Lilly 1,137.66 Bn 1,106.24 Bn 19.71 Bn 85.78%
2 Johnson & Johnson 636.13 Bn 556.00 Bn 17.30 Bn 68.12%
3 AbbVie 505.28 Bn 478.39 Bn 12.70 Bn 74.74%
4 Merck 358.10 Bn 312.48 Bn 12.21 Bn 73.54%
5 Novartis Ag 292.59 Bn 256.58 Bn 11.24 Bn 78.02%
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn 83.60%
7 Amgen 237.53 Bn 192.93 Bn 7.24 Bn 72.04%
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn 79.76%
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn 72.78%
10 Xenetic Biosciences 4.02 Mn -21.81 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2017 -14.15%
May 31, 2013 74.81%
Feb 28, 2013 89.24%
Nov 30, 2012 63.79%
May 31, 2012 100.00%
Feb 29, 2012 76.03%
Nov 30, 2011 89.70%
API Access

Xenetic Biosciences Gross Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gross-margin&ticker=XBIO&period=max&api_key=YOUR_API_KEY